IPP Bureau
Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr
By IPP Bureau - December 09, 2024
Aims to become India’s leading cancer testing company
Briefs: Venus Remedies and GPT Healthcare
By IPP Bureau - December 07, 2024
Venus Remedies secures marketing authorization in Philippines
Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease
By IPP Bureau - December 07, 2024
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy
By IPP Bureau - December 07, 2024
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
By IPP Bureau - December 07, 2024
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
AstraZeneca appoints Iskra Reic as Executive Vice President, International
By IPP Bureau - December 06, 2024
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination
By IPP Bureau - December 06, 2024
For people with relapsed or refractory diffuse large B-cell lymphoma
Lupin’s R&D facility in Pune bags LEED Platinum Certification
By IPP Bureau - December 06, 2024
Reaffirms Lupin’s commitment to sustainable resource management
Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
By IPP Bureau - December 06, 2024
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands
By IPP Bureau - December 05, 2024
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Granules India update on USFDA inspection at Gagillapur facility
By IPP Bureau - December 05, 2024
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
Alembic Pharmaceuticals gets USFDA tentative approval for OTC
By IPP Bureau - December 05, 2024
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Lupin gets tentative approval from USFDA for Sitagliptin and Metformin Hydrochloride Tablets
By IPP Bureau - December 05, 2024
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Aster and Blackstone-backed Quality Care to merge and create hospital chains in India
By IPP Bureau - December 04, 2024
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
